1型神经纤维瘤病的系统性免疫失调:特应性多病的转化验证
研究利用TriNetX全球网络纳入23,218例1型神经纤维瘤病患者并按1:1倾向评分匹配对照,评估特应性多病新诊断风险。结果显示患者特应性皮炎、哮喘、过敏性鼻炎、荨麻疹及特应性角结膜炎风险均显著升高,提示该病存在系统性神经免疫失调。
要点
- 1型神经纤维瘤病患者特应性皮炎风险显著升高(aHR=7.45)。
- 特应性角结膜炎风险升高尤为突出(aHR=17.35)。
- 上述关联在成人、女性及其他种族中更明显。
核心结论
- 1型神经纤维瘤病的神经炎症驱动不限于肿瘤发生,还表现为广泛的系统性神经免疫失调。
研究设计与样本
- 使用TriNetX全球网络识别23,218例1型神经纤维瘤病患者,并按1:1倾向评分匹配对照。
- 采用Cox比例风险回归模型估计调整风险比(aHR)。
主要发现
- 特应性皮炎风险升高(aHR=7.45;95%CI=4.18-13.28)。
- 哮喘风险升高(aHR=4.68;95%CI=3.72-5.90)。
- 过敏性鼻炎风险升高(aHR=7.15;95%CI=5.52-9.25)。
- 荨麻疹风险升高(aHR=3.54;95%CI=2.28-5.48)。
- 特应性角结膜炎风险升高(aHR=17.35;95%CI=6.92-43.50),所有P<.0001。
临床怎么用
- 对1型神经纤维瘤病患者应关注特应性多病筛查,尤其是成人、女性及其他种族人群。
- 靶向共享通路可能同时有利于肿瘤控制和系统性炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurofibromin deficiency drives a proinflammatory tumor microenvironment through neuroimmune crosstalk. However, whether this local dysregulation translates into a clinically relevant systemic inflammatory phenotype remains unclear. Using the TriNetX global network, we identified 23,218 individuals with neurofibromatosis type 1 and propensity score-matched them 1:1 with controls. The primary outcomes were new diagnoses of atopic multimorbidity, including atopic dermatitis, asthma, allergic rhinitis, urticaria, and atopic keratoconjunctivitis. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs). Our analysis revealed that patients with neurofibromatosis type 1 exhibited profoundly elevated risks of atopic dermatitis (aHR = 7.45; 95% confidence interval [CI] = 4.18-13.28); asthma (aHR = 4.68; 95% CI = 3.72-5.90); allergic rhinitis (aHR = 7.15; 95% CI = 5.52-9.25); urticaria (aHR = 3.54; 95% CI = 2.28-5.48); and, notably, atopic keratoconjunctivitis (aHR = 17.35; 95% CI = 6.92-43.50) (all P < .0001). Subgroup analyses indicated that these associations were generally more pronounced in adults, females, and other racial groups. These findings provide epidemiological validation that the neuroinflammatory drive in neurofibromatosis type 1 is not confined to tumorigenesis but manifests as a pervasive systemic neuroimmune dysregulation. This implies that targeting shared pathways could offer dual benefits for tumor control and systemic inflammation.
引用
- Chen LY, Liao CP, Weng HJ, et al. Systemic immune dysregulation in neurofibromatosis type 1: Translational validation of atopic multimorbidity. J Invest Dermatol. 2026. PMID: 42035791. doi:10.1016/j.jid.2026.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。